The ®broblast growth factor (FGF) family consists of at least 18 multifunctional polypeptides (Galzie et al., 1997; Hu et al., 1998) . The HST-1 gene, originally identi®ed as a transforming gene from human gastric cancer, encodes FGF-4, a 206-amino acid protein, and is located on chromosome 11q13 (Sakamoto et al., 1986; Taira et al., 1987) . The gene has been isolated and characterized in several other solid malignant tumors (Delli-Bovi et al., 1987) . The FGF family has been shown to be mitogenic toward a broad spectrum of mesodermal, ectodermal, and endodermal cells, inducing cell proliferation and dierentiation in vitro (Wright and Hyang, 1996) . The expression of mouse Hst-1/Fgf-4 transcripts is restricted to the apical ectodermal ridge of the embryonic limb bud, and the mouse Hst-1/Fgf-4 gene works as an inducer of embryonic limb development (Suzuki et al., 1992; Niswander and Martin, 1992; Ochiya et al., 1995; Johnson and Tabin, 1997) . Unlike acidic and basic FGFs, however, the HST-1/FGF-4 gene is normally dormant in adult tissues, and the physiological functions of its product in adults remain unknown.
We have previously shown that an intraperitoneal (i.p.) injection of the adenovirus vector containing human HST-1/FGF-4 cDNA (Adex1HST-1) into mice caused a continuous increase in serum HST-1 protein and a twofold increase in the peripheral platelet count for a period of approximately 30 days . We also showed that, with thrombopoietin, HST-1/FGF-4 stimulated the proliferation of megakaryocyte progenitors synergistically. It was also indicated that HST-1/FGF-4 can regulate megakaryocyte development not only as a megakaryocyte potentiating factor, but also as an inducer of IL-6 and TNF-a secretion from megakaryocytes (Konishi et al., 1996) . Based on these observations, eective prevention of experimentally induced thrombocytopenia was attained by the use of Adex1HST-1 and was accompanied by an increased count of megakaryocytes in bone marrow with no histological abnormalities and without impairment of the platelet functions (Konishi et al., 1995) .
Bone marrow injury and damage on the intestinal tract often results from cancer treatment that employs chemotherapeutics and radiation. A variety of cytokines such as GM-CSF, G-CSF, stem cell factor (SCF), TNFa and IL-1, polysaccharides (Ainsworth, 1988) and prostaglandins (Hanson and Thomas, 1983; van Buul et al., 1997) have been developed over the past 15 years, and have been tested for their ability to prevent or treat bone marrow suppression (Maisin, 1998; Neta, 1988) . However, known cytokines and various radioprotective chemicals cannot eectively prevent injury after exposure to a lethal radiation dose (Maisin, 1998) .
In an attempt to assess the radio-protective eectiveness of HST-1/FGF-4, we injected 1610 9 plaque forming units (p.f.u.) of Adex1HST-1, which was puri®ed through CsCl step gradient centrifugation as described (Kanegae et al., 1994) and adjusted to 1610 9 p.f.u./ml, i.p. into mice 3 days prior the 9.0 Gy irradiation. In this prevention model, mice exhibited a dramatic and signi®cant increase in survival (P50.0001) compared with control animals adminis-tered 1610 9 p.f.u. of control Adex1wt which is a replication de®cient recombinant adenovirus carrying the SRa promoter and SV40 poly(A) + signal ( Figure  1a) . Pretreatment with Adex1HST-1 led to a signi®cant reduction in radiation-induced body weight loss as compared to the control mice injected with Adex1wt (data not shown). Thus, the Adex1HST-1 injection signi®cantly prevented radiation injuries.
To investigate the therapeutic eects of Adex1HST-1 against lethal irradiation, mice were administered 1610 9 p.f.u. of Adex1HST-1 or control Adex1wt i.p. 6 h after the 9.0 Gy irradiation. Mice administered Adex1HST-1 exhibited a 20% increase in survival (P50.04) as compared to the control animals ( Figure  1b) . Thus, the Adex1HST-1 injection after irradiation had a small but signi®cant therapeutic eect.
We next examined the serum concentration of HST-1/FGF-4 protein by ELISA in irradiated animals before and after the administration of adenoviruses. On day 7, the serum HST-1/FGF-4 protein levels in mice injected with Adex1HST-1 prior to irradiation and in mice with injected Adex1HST-1 6 h postirradiation were 420+57 and 397+45 ng/ml, respectively. Representative kinetic data were obtained from one animal in each group (Figure 2 ). Although data are not shown, irradiated mice administered with Adex1wt showed no increase in the serum HST-1/ FGF-4 level. These results suggest that the administration of Adex1HST-1 resulted in successful expression of the HST-1/FGF-4 gene leading to increased serum HST-1/FGF-4 protein, which was not disturbed by the irradiation regimens.
Adex1HST-1 increased the number of mature marrow megakaryocytes in thrombocytopenic mice (Konishi et al., 1995) . To examine the eects of Adex1HST-1 on peripheral hematological parameters of irradiated mice, peripheral blood samples were analysed. Twenty days after the irradiation, platelet count, red blood cell count, white blood cell count and hemoglobin concentration were all increased in mice administered Adex1HST-1 (Table 1 ). In contrast, mice administered control Adex1wt before or after the irradiation showed severe myelosuppression. The decrease in hematological counts was prevented by administration of Adex1HST-1 of mice with Adex1HST-1 6 h after the irradiation. However, that prevented eects were much more signi®cant when Adex1HST-1 was administered before irradiation.
Histological examination revealed that Adex1HST-1 injected groups showed no signi®cant adverse eects in cell number in the bone marrow (Figure 3a . Although damage to cells was clearly observed in the histological sections of bone marrow from mice administered Adex1HST-1, pretreatment with Adex1HST-1 reduces the injuries to hematopoietic cells as compared to control mice administered Adex1wt. Mice administered Adex1HST-1 showed splenomegaly and there were extramedullary hematopoiesis in the spleen. In contrast, the spleen from mice administered Adex1wt showed atrophic Figure 1 The eect of Adex1HST-1 on survival following girradiation with a single dose of 9 Gy. All mice received girradiation from a 60 Co source (Gammacell 220, Atomic Energy of Canada) at a dose of 9 Gy delivered at a dose rate of 0.75 Gy/s. This whole-body irradiation regimen induces lethality in mice most likely as a result of lethal marrow and intestinal injuries (Wambersie et al., 1996) . (a) Mice were injected intraperitoneally (i.p.) with a single dose of 1610 9 p.f.u. of Adex1HST-1 or control Adex1wt viruses 3 days prior to irradiation. (b) Mice were injected i.p. with adenovirus 6 h after irradiation. Each arm of the experimental group contained 20 animals. The Kaplan-Meier method was used to estimate survival as a function of time and survival dierences were analysed by the log-rank test. Statistical dierences were assessed using Student's t-test. P values less than 0.05 were considered signi®cant. C57BL/ 6 mice (female, 10 weeks of age) weighing 18 g were purchased from Charles River Japan (Yokohama, Japan) and used for all the experiments. Animal experiments were done under the guidelines of the National Cancer Center Research Institute Figure 2 The serum concentrations of HST-1/FGF-4 protein by ELISA in irradiated animals. The amount of serum HST-1/FGF-4 protein was detected by indirect ELISA using mouse antihuman FGF-4 monoclonal IgG (R&D Systems, USA) as described . Mice injected with a single dose of 1610 9 p.f.u. of Adex1HST-1 3 days prior to irradiation (*). Mice administered Adex1HST-1 6 h after irradiation (*). Arrows indicate the time of injection of Adex1HST-1 Figure 3 Histological demonstration of protective eects of Adex1HST-1 in irradiated mice. Fourteen days after the irradiation, mice were sacri®ced, pieces of bone marrow, spleen and intestine were removed and ®xed in 4% formaline/PBS for histological examinations. Tissue sections including bone marrow (a,b), spleen (c,d) and small intestine (e,f) were analysed. Adex1HST-1 injected animals: (a,c) and (e), Adex1wt injected animals; (b,d) and (f). Bar, 500 mm Mice were injected with a single dose of 1610 9 p.f.u. of 1 Adex1HST-1 or control Adex1wt viruses intraperitoneally 3 days before or 6 h after 9 Gy irradiation. Twenty days after the irradiation, blood samples for platelet count were drawn from the retro-orbital vein with a capillary pipette (Unopette, Becton Dickinson). Platelet number was peripheral with a Neubauer hemacytometer under microscope. For the other peripheral hematological parameters, total blood was drawn from the heart of the anesthetized mice. Number of animals is four (3 days before) and three (6 h after) in each group changes with loss of wet organ weight, compared with mice prior to irradiation. There were no signi®cant histological changes in intestinal tract after irradiation when the mice were injected Adex1HST-1: crypt depth and villus length of intestines from mice administered Adex1HST-1 were not signi®cantly dierent from those of mice that had not received irradiation (unpublished observation). In contrast, there were severe damage in intestinal tract of Adex1wt administered mice after irradiation. These results revealed that HST-1/FGF-4 pretreatment signi®cantly reduced radiation-induced injury not only in hematopoietic tissues but also in the small intestine.
The present study demonstrates that a single administration of adenoviruses carrying the human HST-1/FGF-4 gene ameliorated injuries caused by an otherwise lethal dose of radiation. In particular, pretreatment of mice with Adex1HST-1 yielded quite signi®cant survival after irradiation, which had lethal eects on the control group. The surviving mice administered Adex1HST-1 exhibited far fewer adverse eects on all hematological parameters. In addition, histopathological analysis revealed that the protective eects of Adex1HST-1 against irradiation were not limited to hematopoietic tissues, and that intestinal tract injury was also signi®cantly prevented. The administrations of Adex1HST-1 after irradiation were much less eective in protecting against lethal irradiation, although Adex1HST-1 treatment after irradiation certainly prolonged the survival time. Similar kinetics of HST-1/FGF-4 serum levels were obtained between the pre-and post-irradiated mice. These results indicated that HST-1/FGF-4 works much less eectively on radiation-damaged hematopoietic cells and intestinal cells than on the intact cells.
Damage to the hematopoietic system is frequently a serious side eect of cancer chemotherapy and radiation therapy (Blumenthal et al., 1995) . In particular, damage to leukocyte and megakaryocyte progenitors can result in severe clinical consequences such as sepsis and hemorrhage (Verrees et al., 1996) . Administration of Adex1HST-1 led to a signi®cantly increased platelet count in normal mice, but no signi®cant increase in red blood cell counts and leukocyte counts were observed in non-irradiated mice after Adex1HST-1 treatment . Injections of Adex1HST-1 i.p. into lethally irradiated mice resulted in an increase not only in platelet count, but also in red blood cell count, whiteblood cell count and hemoglobin concentration. Thus, a recombinant adenovirus vector carrying HST-1/FGF-4 can prevent the depression of all the peripheral hematological parameters. It remains to be elucidated why HST-1/ FGF-4 administration aects all the hematological parameters in irradiated mice, while having eects only on platelet counts in normal cells.
The mechanism through which FGF stimulates hematopoiesis in vivo has not been established. The most obvious eect of FGF on hematopoiesis is on the cells of the stromal layer. In vitro data have shown that stromal cells are necessary for the survival, proliferation, and dierentiation of hematopoietic cells (Wilson et al., 1991) . An addition of HST-1/FGF-4 to human long-term bone marrow cultures increased both the cell density of the stromal layer and the number of hematopoietic colony forming cells in the cultures in a dose-dependent manner (Quito et al., 1996) . In fact, several members of the FGF family receptors were shown to be expressed in the hematopoietic cells, demonstrating the presence of these receptors in the lineage and suggesting that hematopoietic cells could be FGF-responsive (Kato et al., 1992) . These data indicate that HST-1/FGF-4 may possibly augment the in situ cytokine milieu by increasing the number of stromal cells and megakaryocytes, which are capable of producing hematopoietic cytokines, possibly resulting in multilineage hematopoietic stimulation.
The protective eects of HST-1/FGF-4 are apparently directed toward hematological cells in the bone marrow and spleen, but multiple indirect systemic advantages were also evident in these models. Mucositis is a common side eect of many anticancer therapies (Sonis, 1998) . The surviving Adex1HST-1 treated mice exhibited maintenance and regeneration of the intestinal mucosa, which may ensure normal food and water intake and protect these injured mice from infection by enteric microorganisms. In fact, the surviving mice administerd Adex1HST-1 showed no signi®cant weight loss during the course of the experiments. Although there is no direct evidence that the recombinant HST-1/FGF-4 protein itself showed an ability to increase the growth of crypt stem cells in the small intestine of normal mice, the result that HST-1/FGF-4 has a potent growth promoting factor towards epithelial cells as well as stem cells (Lamb et al., 1996) gives a basis for suggesting that Adex1HST-1 may have promoted the intestinal regenerative capacity in the mice with lethal irradiation. Therefore, the data presented here demonstrate that HST-1/FGF-4 may be therapeutically useful in lessening the severe mucositis associated with cancer therapy regimens.
HST-1/FGF-4 has a number of biological activities: it has potent transforming potential, apparently through an autocrine mechanism of action (Wright and Huang, 1996) , and it acts as a potent angiogenic factor (Yoshida et al., 1994; Deroanne et al., 1997) . Therefore, there is potential for HST-1/FGF-4 to stimulate tumor growth in vivo when Adex1HST-1 is used in the clinical setting for anti-cancer therapy. The amount of Adex1HST-1 used in this experiment did not alter the growth rate or neovascularization of tumors implanted with HST-1-transformed NIH3T3 cells (Sakamoto et al., 1986) in nude mice (unpublished observations). Although further careful analyses are required, these observations suggest that a therapeutically eective dose of Adex1HST-1 may not cause tumor progression in patients undergoing radiation therapy.
Recently, Farrel et al. (1998) have reported that recombinant human keratinocyte growth factor (KGF) could protect mice from chemotherapy-and radiationinduced gastrointestinal injury and mortality. However, in whole-body radiation models subjected to over 9 Gy of radiation, pretreatment of mice with KGF did not protect them from death from intestinal and marrow toxicities. Although another interesting approach to crypt survival has been done by the use of IL-11 and TGF-b (Potten, 1995; Du et al., 1994; Potten et al., 1997; Booth and Potten, 1995) , the focus of these studies is on injuries of intestinal epithelia. In this regard, our adenovirus vector carrying the HST-1/ FGF-4 gene is superior to any other protective eects Radioprotective effect of HST-1/FGF-4 Y Takahama et al of cytokines against a lethal dose of irradiation, probably due to the fact that HST-1/FGF-4 targets both bone marrow and intestinal injuries. This dual eect of HST-1/FGF-4 may lend strong support to the concept of the therapeutic eectiveness of adenoviruses carrying HST-1/FGF-4 in systemic injuries from irradiation.
